Related Experiment Video
Updated: Jan 23, 2026

A Proteoliposome-Based Efflux Assay to Determine Single-molecule Properties of Cl- Channels and Transporters
Published on: April 20, 2015
Tumor Site-Dependent Transport Properties Determine Nanotherapeutics Delivery and Its Efficacy
Megumi Kai1, Arturas Ziemys1, Yan Ting Liu1
1Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Street, Houston, TX 77030, USA.
Abstract:
Insufficient delivery of systemically administered anticancer drugs to tumors can compromise therapeutic efficacy and develop drug delivery-based therapeutic resistance. Nanotherapeutics such as PEGylated liposomal doxorubicin (PLD) are designed to preferentially accumulate in tumors utilizing enhanced permeation and retention effect. However, their antitumor effects and resulting clinical outcomes are modest and heterogeneous among tumors. Here, we aimed to investigate whether the amount and efficacy of PLD delivered to tumors are tumor site dependent. We established orthotopic primary tumor or liver metastases models of murine breast cancer using 4 T1 cells. PLD showed significant therapeutic effects against tumors that grew in primary mammary sites but not in the liver. We found that differences in therapeutic efficacy were not because of the intrinsic biological resistance of cancer cells but rather were associated with tumor site-dependent differences in transport properties, such as the amount of PLD delivery, blood vessel function, relative vascular permeability, and mechanical pressure in tumors. Thus, transport properties in tumor is site dependent and can be used as phenotypic surrogate markers for tumor drug delivery and therapeutic efficacy.
Insights
PEGylated liposomal doxorubicin (PLD) effectively treats primary tumors but not liver metastases. Tumor site-specific transport properties, not cell resistance, dictate PLD delivery and therapeutic efficacy.
Area of Science:
- Oncology
- Nanomedicine
- Pharmacology
Background:
- Systemic anticancer drug delivery to tumors is often insufficient, leading to resistance.
- Nanotherapeutics like PEGylated liposomal doxorubicin (PLD) aim to improve tumor accumulation via the enhanced permeation and retention effect.
- Current clinical outcomes for PLD are modest and vary significantly between tumors.
Purpose of the Study:
- To investigate if the delivery and efficacy of PLD are dependent on the tumor site.
- To understand the factors contributing to heterogeneous therapeutic outcomes of PLD.
Main Methods:
- Establishment of orthotopic primary breast cancer and liver metastasis models in mice using 4T1 cells.
- Administration of PLD and assessment of therapeutic effects.
- Analysis of tumor transport properties, including PLD delivery, vascular function, permeability, and mechanical pressure.
Main Results:
- PLD demonstrated significant therapeutic effects in primary mammary tumors.
- PLD showed minimal therapeutic effects in liver metastases.
- Differences in efficacy were attributed to tumor site-dependent transport properties, not intrinsic cancer cell resistance.
Conclusions:
- Tumor site significantly influences the transport properties of nanotherapeutics like PLD.
- Factors such as PLD delivery amount, vascular function, permeability, and pressure vary by tumor location.
- Tumor transport properties can serve as predictive markers for nanotherapeutic delivery and efficacy.
Related Concept Videos
Facilitated Transport
Self-Efficacy
Contact-dependent Signaling
Gap Junctions
In animal cells, gap junctions are formed...
Regulated mRNA Transport
Primary Active Transport
Secondary Active Transport

